Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer
Related Posts
Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin[...]
Harbeck N, Dieras V, Gelmon KA, Finn RS, Martin M, Neven P, Kim S, Ma J, Gauthier E, Broughton E, Doan J, Rugo HS. Effect[...]
Dummer R, Sandhu S, Miller WH, Butler MO, Taylor MH, Heinzerling L, Blank CU, Munoz-Couselo E, Burris HA, Postow MA, Chmielowski B, Middleton MR, Berking[...]